22 results
8-K
EX-99.1
ANNX
Annexon Inc
4 Mar 24
Regulation FD Disclosure
5:25pm
and Peripheral Nerve Society Annual Meetings 2021-2022.
Annexon Has a Deep-Rooted History and Commitment to GBS Aligned With Our Mission Strong Scientific
424B5
ANNX
Annexon Inc
21 Dec 23
Prospectus supplement for primary offering
4:05pm
and presented at the American Society of Retina Specialists (ASRS) Annual Meeting in July 2023 showed that ANX007 provided statistically significant … presented at the American Society of Nephrology’s Kidney Week 2023 conference, which showed subcutaneous ANX009 was well tolerated and demonstrated plasma
8-K
EX-99.3
ANNX
Annexon Inc
20 Dec 23
Regulation FD Disclosure
5:17pm
modeling that similar 4th Syfovre study demonstrates positive visual acuity Summary: BCVA Findings for Syfovre From Heier, Retina Society, November 2-5
8-K
EX-99.1
ANNX
Annexon Inc
20 Dec 23
Regulation FD Disclosure
5:17pm
at the American Society of Retina Specialists (ASRS) Annual Meeting in July 2023 showed that ANX007 provided statistically significant, time and dose
8-K
EX-99.1
4lfi4p
13 Nov 23
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
q7azp4vge2f66ji20tam
24 Oct 23
Annexon Receives Prime Designation from the Ema for ANX007 for the Treatment of Geographic Atrophy
4:30pm
8-K
EX-99.1
zmajs76
7 Aug 23
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
4:12pm
8-K
EX-99.2
vpbypums0s2h bf6419
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm
8-K
EX-99.1
lk6 rgjjnew
3 Nov 22
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
6:45am
8-K
EX-99.1
soryf146ljec v6arvc
16 Aug 21
Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update
4:11pm
424B4
gsqd04 ppb
24 Jul 20
Prospectus supplement with pricing info
5:15pm
S-1/A
jxl awb9k0
20 Jul 20
IPO registration (amended)
6:07am
S-1
kr760 c5cek14r1gk
2 Jul 20
IPO registration
12:00am
DRS/A
dyg08dpu
26 Feb 20
Draft registration statement (amended)
12:00am
DRS/A
ewj4bd
6 Dec 19
Draft registration statement (amended)
12:00am